Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.24 EUR
−94.38 M EUR
45.97 M EUR
63.31 M
About ZEALAND PHARMA A/S
Sector
CEO
Adam Sinding Steensberg
Headquarters
Soborg
Website
Founded
1997
ISIN
DK0060257814
FIGI
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 22Z is 98.60 EUR — it has increased by 1.02% in the past 24 hours. Watch ZEALAND PHARMA A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ZEALAND PHARMA A/S stocks are traded under the ticker 22Z.
22Z stock has risen by 5.74% compared to the previous week, the month change is a −10.20% fall, over the last year ZEALAND PHARMA A/S has showed a 4.56% increase.
We've gathered analysts' opinions on ZEALAND PHARMA A/S future price: according to them, 22Z price has a max estimate of 147.39 EUR and a min estimate of 109.20 EUR. Watch 22Z chart and read a more detailed ZEALAND PHARMA A/S stock forecast: see what analysts think of ZEALAND PHARMA A/S and suggest that you do with its stocks.
22Z stock is 1.59% volatile and has beta coefficient of 0.99. Track ZEALAND PHARMA A/S stock price on the chart and check out the list of the most volatile stocks — is ZEALAND PHARMA A/S there?
Today ZEALAND PHARMA A/S has the market capitalization of 6.90 B, it has decreased by −3.24% over the last week.
Yes, you can track ZEALAND PHARMA A/S financials in yearly and quarterly reports right on TradingView.
ZEALAND PHARMA A/S is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
22Z earnings for the last quarter are −0.50 EUR per share, whereas the estimation was −0.48 EUR resulting in a −5.61% surprise. The estimated earnings for the next quarter are −0.56 EUR per share. See more details about ZEALAND PHARMA A/S earnings.
ZEALAND PHARMA A/S revenue for the last quarter amounts to 591.75 K EUR, despite the estimated figure of 8.93 M EUR. In the next quarter, revenue is expected to reach 8.59 M EUR.
22Z net income for the last quarter is −35.71 M EUR, while the quarter before that showed −39.17 M EUR of net income which accounts for 8.83% change. Track more ZEALAND PHARMA A/S financial stats to get the full picture.
No, 22Z doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 1, 2024, the company has 253.00 employees. See our rating of the largest employees — is ZEALAND PHARMA A/S on this list?
Like other stocks, 22Z shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZEALAND PHARMA A/S stock right from TradingView charts — choose your broker and connect to your account.